Originally published by our sister publication Clinical Oncology News
The FDA has granted accelerated approval to afamitresgene autoleucel (Tecelra, Adaptimmune LLC), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy; are HLA-A*02:01P, -A*02:02P, -A*02:03P or -A*02:06P positive; and whose tumor expresses the MAGE-A4 antigen as determined by